Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. But so far, the company is ...

A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag ...

BMS thanks the patients, families and investigators for their contributions to this important clinical trial.” Published first on TheFly – the ultimate source for real-time, market-moving ...

A viewer called to ask about Bristol-Myers Squibb Company (NYSE:BMY) and if they should hold it. This is what Cramer had to say: “No, no, you don’t hold it. You buy more. This COBENFY is this ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

A brand-new State of Play has arrived and it gave us an exciting look at the future of PS5 with a ton of games. Alongside an exciting look at Saros, Housemarque's next game of Returnal, we also ...

Serving as Television Editor since 2018, Ray began five years earlier as a contributing writer/photographer before being brought onto the core BC team in 2017.